Last reviewed 2026-04-20 · How we verify

GAMUNEX-C

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Headache
• Nausea
• Fever
• Diarrhea
• Rash
• Pyrexia
• Local infusion site reactions
• Fatigue
• Upper respiratory tract infection
• Arthralgia
• Sinusitis
• Bronchitis

Serious adverse events

• Autoimmune pure red cell aplasia
• Coombs negative hypochromic anemia
• Anaphylactic reactions
• Anaphylactoid reactions
• Severe chills

Key clinical trials

• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
• Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia (PHASE2)
• A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
• Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease (PHASE3)
• Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (PHASE3)
• IVIG vs SCIG in CIDP (PHASE1)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (PHASE3)
• A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GAMUNEX-C CI brief — competitive landscape report
• GAMUNEX-C updates RSS · CI watch RSS
• Grifols Therapeutics LLC portfolio CI